by institution – Page 3 – Retraction Watch

Duke group retracts Nature journal paper

A Nature journal is retracting a 2018 research letter about the genetics of flower patterns over concerns about the reliability of the data.

The letter, “Two genetic changes in cis-regulatory elements caused evolution of petal spot position in Clarkia,” appeared in Nature Plants and was written by a team of researchers at Duke University, including Mark Rausher, a prominent plant geneticist and the John Carlisle Kilgo Professor of Biology at the institution. The paper has been cited 12 times, according to Clarivate Analytics’ Web of Science.

Per the retraction notice:

“Statins May Cut Glaucoma Risk,” said a New York Times headline. But is that true?

Last year, JAMA Ophthalmology published a study that claimed to find a link between using cholesterol-lowering drugs known as statins and a reduced risk of glaucoma. In a New York Times story on the paper, lead author

Jae H. Kang, an assistant professor of medicine at Brigham and Women’s Hospital in Boston, suggested that statins reduce pressure in the eye, help maintain good blood flow and may help protect the optic nerve.

But Kang came to realize, while reviewing the results for another study, that her research had a major error, as she writes in a letter accompanying the retraction and replacement of the study. Kang tells Retraction Watch:

Fourth retraction for Haruko Obokata, focus of STAP cell scandal, after Harvard investigation

More than five years after Nature retracted two highly suspect papers about what had been described as a major breakthrough in stem cell research, another journal has pulled a paper about the work.

The scandal over so-called STAP stem cells took down more than just a few articles. The case centered on Haruko Obokata, a Japanese researcher who conducted the studies as a post-doc in the Harvard lab of Charles Vacanti. Obokata lost her doctoral thesis from Waseda University in 2015 because it plagiarized from the U.S. National Institutes of Health. She also retracted a paper in Nature Protocols.

Harvard group retracts Nature paper

A group of researchers based at Harvard University have retracted an influential 2017 letter in Nature after a change in lab personnel led to the discovery of errors in the analysis.

The article, “Microglia-dependent synapse loss in type I interferon-mediated lupus,” emerged from a collaboration including scientists at Harvard Medical School, the Rockefeller University in New York City, the University of Magdeburg, in Germany.

The senior author of the research letter — which has been cited 75 times, earning it a highly cited designation from Clarivate Analytics’ Web of Science — was Michael C. Carroll, a prominent immunology researcher. [See disclosure at the end of this post.] Also on the list was Ronald Herbst, who at the time was vice president of research at MedImmune but has since left that company for another biotech firm. The first author was Allison Bialas, at the time a post-doc at Harvard.

According to the abstract:

Duke misconduct case prompts another expression of concern — but not a retraction

Here’s an expression of concern that raised some eyebrows around the Retraction Watch HQ.

NIH to lift Duke sanctions stemming from misconduct

The U.S. National Institutes of Health (NIH) plans to lift sanctions it placed on Duke University more than 1.5 years ago following concerns about how the school responded to recent cases of misconduct.

In a memo today to faculty and staff obtained by Retraction Watch, Lawrence Carin, Duke vice president for research wrote:

Cancer lab at Harvard subject of inquiry

Harvard has investigated work from the lab of a cancer researcher at Beth Israel Deaconess Medical Center that has been under scrutiny on PubPeer for more than five years.

Questions about the output of the lab, run by James W. Mier, began appearing on PubPeer in 2014, with comments about images that looked manipulated. The pseudonymous whistleblower Clare Francis sent Gretchen Brodnicki, Harvard Medical School’s dean for faculty and research integrity, an email about those comments on Sept. 27, 2014, and on July 24 of this year, Brodnicki asked Francis to resend that email.

Also that month, the journal Clinical Cancer Research issued an expression of concern for a 2006 paper by Mier and colleagues, which stated:

Drip, drip: Former Harvard stem cell researcher up to 18 retractions

Piero Anversa, a former star researcher at Harvard Medical School who left the institution under a cloud, is up to 18 retractions. But that’s barely half of the 31 papers by Anversa’s group that Harvard has requested journals pull over concerns about the integrity of the findings.

The two articles, published in the Proceedings of the National Academy of Sciences, appeared in 2008 and 2009. Anversa and a frequent co-author, Annarosa Leri, are among the authors on each.

Anversa ran a richly-funded lab at Brigham and Women’s Hospital studying cardiac stem cells. But in 2014, critics began publicly questioning the output from the lab — questions that led to the departure of Anversa and Leri and a $10 million payout from the Brigham and Partners Healthcare to settle allegations of fraud involving the work. Anversa and Leri also sued Harvard — unsuccessfully — for alerting journals to the investigation and allegedly costing them job offers.

The retraction notice for the 2008 paper, “Notch1 regulates the fate of cardiac progenitor cells,” reads:

Columbia historian stepping down after plagiarism finding

A tenured professor of history at Columbia University will be stepping down at the end of next year after an investigating committee at the school found “incontrovertible evidence of research misconduct” in his controversial 2013 book.

Charles King Armstrong, the Korea Foundation Professor of Korean Studies in the Social Sciences, was found to have “cited nonexistent or irrelevant sources in at least 61 instances” in “Tyranny of the Weak: North Korea and the World, 1950-1992,” according to the Columbia Spectator, which first reported on the resignation last week.

In a September 10 letter, Maya Tolstoy, dean of the Faculty of Arts and Sciences, announced the news to the institution:

“Highly unusual and unfortunate error” delays retraction two years in high-profile Duke case

As we’ve noted before, “the wheels of scientific publishing turn slowly … but they do (sometimes) turn.”

More than six years after the first retraction for Erin Potts-Kant, who was part of a group at Duke whose work would unravel amid misconduct allegations and lead to a $112.5 million settlement earlier this year with the U.S. government — and two years after a journal says it first became aware of the issues — a retraction by the group has appeared in Pediatric Research, a Springer Nature title.

Here’s the retraction notice for “Intra-amniotic LPS amplifies hyperoxia-induced airway hyperreactivity in neonatal rats”:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: